Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
2023
Abstract
Patients with polycythemia vera are at the increased risk of thrombotic events. Therapy with ropeginterferon alpha 2b leads to higher hematological and cytogenetic remission in comparison with standard therapy, based on two clinical trials Two clinical trials- Proud PV and Proud continuation PV.
After 7 year of evaluation, it is obvious, that also trombotic events are decreased with ropeginterferon therapy.